Aurobindo Pharma gets US FTC’s nod to acquire Lannett Company

Aurobindo Pharma gets US FTC’s nod to acquire Lannett Company

Aurobindo Pharma’s US subsidiary receives US FTC approval to acquire Lannett Company for $250 million, strengthening its position in non-opioid controlled substances and domestic manufacturing.

Aurobindo Pharma USA receives FTC approval for Lannett acquisition

Aurobindo Pharma USA, Inc. (Aurobindo USA), a wholly owned subsidiary of Aurobindo Pharma, has received approval from the U.S. Federal Trade Commission (FTC) to proceed with the acquisition of Lannett Company LLC (Lannett). The transaction, valued at $250 million on a cash-free, debt-free basis and inclusive of normalised working capital, is expected to close before the end of June 2026. Lannett, a Pennsylvania-based generic pharmaceutical compa…